+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID05727176

Phase 2 Randomized Study of Futibatinib 16 mg and 20 mg Oral Tablets in Patients With Advanced Cholangiocarcinoma With FGFR2 Gene Fusions or Rearrangements

Led by Taiho Oncology, Inc. · Updated on 2026-09-01

120

Participants Needed

65

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating futibatinib, an oral FGFR inhibitor, in patients with advanced cholangiocarcinoma CCA that have FGFR2 gene fusions or rearrangements. This multinational Phase 2 study aims to confirm the clinical benefit of a 20 mg dose and assess the safety and effectiveness of a 16 mg dose in patients who have previously received treatment for their CCA. Participants are randomly assigned to one of two groups one receiving 16 mg of futibatinib daily and the other receiving 20 mg daily. Both treatments are taken orally every day in 21-day cycles. Patients may continue receiving the medication until their disease progresses or other withdrawal criteria are met. During the study, participants undergo assessments including imaging to measure tumor response, safety monitoring for side effects, and quality of life evaluations. Researchers will evaluate outcomes such as the objective response rate, duration of response, progression-free survival, overall survival, and adverse events up to 12 months after the study ends. The total participation duration depends on individual treatment response and disease progression.

CONDITIONS

Brief Title

Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement

Research Team

T

Taiho Oncology, INC

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here